<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>16(1)</volume><submitter>El Bounkari O</submitter><pubmed_abstract>Atherosclerosis is the underlying cause of myocardial infarction and ischemic stroke. It is a lipid-triggered and cytokine/chemokine-driven arterial inflammatory condition. We identify D-dopachrome tautomerase/macrophage migration-inhibitory factor-2 (MIF-2), a paralog of the cytokine MIF, as an atypical chemokine promoting both atherosclerosis and hepatic lipid accumulation. In hyperlipidemic Apoe&lt;sup>-/-&lt;/sup> mice, Mif-2-deficiency and pharmacological MIF-2-blockade protect against lesion formation and vascular inflammation in early and advanced atherogenesis. MIF-2 promotes leukocyte migration, endothelial arrest, and foam-cell formation, and we identify CXCR4 as a receptor for MIF-2. Mif-2-deficiency in Apoe&lt;sup>-/-&lt;/sup> mice leads to decreased plasma lipid levels and suppressed hepa</pubmed_abstract><journal>Nature communications</journal><pagination>2297</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11889166</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>An atypical atherogenic chemokine that promotes advanced atherosclerosis and hepatic lipogenesis.</pubmed_title><pmcid>PMC11889166</pmcid><pubmed_authors>Kempf WE</pubmed_authors><pubmed_authors>Haid M</pubmed_authors><pubmed_authors>Kontos C</pubmed_authors><pubmed_authors>Brandhofer M</pubmed_authors><pubmed_authors>Bucala R</pubmed_authors><pubmed_authors>Schulz C</pubmed_authors><pubmed_authors>Zan C</pubmed_authors><pubmed_authors>Zarwel M</pubmed_authors><pubmed_authors>Hoffmann A</pubmed_authors><pubmed_authors>El Bounkari O</pubmed_authors><pubmed_authors>Rath D</pubmed_authors><pubmed_authors>Riols F</pubmed_authors><pubmed_authors>Sachs N</pubmed_authors><pubmed_authors>Harm T</pubmed_authors><pubmed_authors>Gokce O</pubmed_authors><pubmed_authors>Ji H</pubmed_authors><pubmed_authors>Megens RTA</pubmed_authors><pubmed_authors>Bourilhon P</pubmed_authors><pubmed_authors>Weber C</pubmed_authors><pubmed_authors>Yang B</pubmed_authors><pubmed_authors>Wagner J</pubmed_authors><pubmed_authors>Messerer D</pubmed_authors><pubmed_authors>Ebert S</pubmed_authors><pubmed_authors>Bugar E</pubmed_authors><pubmed_authors>Kapurniotu A</pubmed_authors><pubmed_authors>Bernhagen J</pubmed_authors><pubmed_authors>Jansen Y</pubmed_authors><pubmed_authors>Doring Y</pubmed_authors><pubmed_authors>Avdic M</pubmed_authors><pubmed_authors>Gawaz M</pubmed_authors><pubmed_authors>Gerra S</pubmed_authors><pubmed_authors>Kramer N</pubmed_authors><pubmed_authors>Maegdefessel L</pubmed_authors><pubmed_authors>Sinitski D</pubmed_authors><pubmed_authors>Milic J</pubmed_authors><pubmed_authors>Bartelt A</pubmed_authors><pubmed_authors>Willemsen N</pubmed_authors></additional><is_claimable>false</is_claimable><name>An atypical atherogenic chemokine that promotes advanced atherosclerosis and hepatic lipogenesis.</name><description>Atherosclerosis is the underlying cause of myocardial infarction and ischemic stroke. It is a lipid-triggered and cytokine/chemokine-driven arterial inflammatory condition. We identify D-dopachrome tautomerase/macrophage migration-inhibitory factor-2 (MIF-2), a paralog of the cytokine MIF, as an atypical chemokine promoting both atherosclerosis and hepatic lipid accumulation. In hyperlipidemic Apoe&lt;sup>-/-&lt;/sup> mice, Mif-2-deficiency and pharmacological MIF-2-blockade protect against lesion formation and vascular inflammation in early and advanced atherogenesis. MIF-2 promotes leukocyte migration, endothelial arrest, and foam-cell formation, and we identify CXCR4 as a receptor for MIF-2. Mif-2-deficiency in Apoe&lt;sup>-/-&lt;/sup> mice leads to decreased plasma lipid levels and suppressed hepa</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Mar</publication><modification>2026-06-01T05:06:50.549Z</modification><creation>2025-04-04T13:11:35.598Z</creation></dates><accession>S-EPMC11889166</accession><cross_references><pubmed>40055309</pubmed><doi>10.1038/s41467-025-57540-z</doi></cross_references></HashMap>